WSC 2023

Lys Therapeutics announces to attend the 15th World Stroke Organization Congress (#WSC2023, 10-12 October 2023) happening right now in #Toronto, Canada.

Lys Therapeutics and Institut BB@C – Blood and Brain @ Caen normandie are proud to be presenting during this international conference new groundbreaking preclinical data using Lys Therapeutics’s monoclonal antibody in ischemic #stroke in combination with #alteplase or #tenecteplase, including in an extended therapeutic window.

Presentation: “Glunomab: a monoclonal antibody counteracting blood-brain barrier disruption induced both by endogenous tPA and fibrinolytic agents (alteplase or tenecteplase) after ischemic stroke”.

Dr. Manuel BLANC, CEO, is happy to meet you there.

💪 All together against Stroke and its dramatic consequences.

———-
#WSC2023 #WSO #Stroke #neurosciences #clinicaltrials #Research #rtpa #TNK #biotech #healthcare #lifesciences #CNS #NeurologicalDiseases #NeurovascularDisorders #innovation #MedicalNeeds #LysTherapeutics #NeuroImmunology #Glunomab #GlunozumabProgram

With the World Stroke Organization, Boehringer Ingelheim, Roche, Inserm, Université de Caen, CYCERON, ADNormandie, Lyonbiopôle and Bpifrance.